Skip to content
Welcome, thoughtbot's Giant Robots listeners!Start here
T-Therapeutics
AI-generated illustration
OrganisationGB

T-Therapeutics

Cambridge biotech making T-cell receptor bispecifics; raised a $133m Series B in November 2026.

Last refreshed: 14 November 2026 · Appears in 1 active topic

Key Question

Can T-cell receptor drugs work in autoimmune disease, where none is approved?

Timeline for T-Therapeutics

#17 10 Nov
#17 5 Nov

Raised a $133m Series B

UK Startups and Innovation: T-Therapeutics raises $133m in Series B
View full timeline →

Background

T-Therapeutics, a University of Cambridge spinout, announced a $133m Series B on 5 November 2026. Advent Life Sciences and the British Business Bank co-led it; the Bank put in £15m and takes a board seat. Eli Lilly, Johnson & Johnson Innovation, Samsara BioCapital and M Ventures joined, and Sofinnova Partners returned.

The company builds T-cell receptor bispecifics: molecules that grip a marker on a diseased cell with one Arm and pull in a killer T cell with the other. The money takes two programmes, one in cancer and one in autoimmune disease, towards clinical proof of concept. Neither has been tested in people, and the targets are undisclosed.

Lilly backed Oyster Therapeutics five days later. For the Bank, the board seat goes further than its lead in Microbiotica's round in October.

Common Questions
Who led T-Therapeutics' Series B?
Advent Life Sciences and the British Business Bank co-led the $133m round on 5 November 2026. The Bank invested £15m and took a board seat.Source: British Business Bank
What is T-Therapeutics developing?
Two T-cell receptor bispecifics, one for cancer and one for autoimmune disease. Neither has yet been tested in people.Source: BioPharm International
How much has T-Therapeutics raised?
It raised a $133m Series B in November 2026 after a $91m Series A, about $224m disclosed in total.Source: BioPharm International
Why did Eli Lilly invest in T-Therapeutics?
Lilly joined as a minority investor behind specialist leads, as it did in Oyster Therapeutics five days later, which gives it an early view of clinical data.Source: BioPharm International
Source Material

Written with AI from Lowdown's published reporting. Not individually reviewed by an editor. Updated 14 November 2026. Editorial standards.